comprehensive -WSS

comprehensive

author：explore 2025-09-27 12:49:01 - browse：87

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： FTC falls short on scrutinizing hospital mergers, study says

hotspot

WSS

Cloning humans is technically possible. It's curious no one has tried

Cancer researcher Catriona Jamieson is sending tumors into space

Element Biosciences CEO lays out genome sequencing strategy

Ask STAT: What do you want to know about ChatGPT in medicine?

Cloning humans is technically possible. It's curious no one has tried

Cloning humans is technically possible. It's curious no one has tried

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

In age of alternative facts, a scholarly course on calling out crap

What would happen to your eyes if you looked at the solar eclipse?

Novavax promises a turnaround & Lilly roils the obesity market

H5N1 bird flu virus started spreading in cows in Texas in December

The high cost of giving birth even with insurance

FTC falls short on scrutinizing hospital mergers, study says

Moonlake's readout produced a cash windfall. Risks remain

#NeedHerScience: shining a light on gender disparities in medicine

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

focus

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Death of patient in Alzheimer’s trial raises question of possible risks

Exact Sciences stock tumbles despite strong cancer detection sales

Do masks work? RCTs can't tell us

The story of mRNA: From a loose idea to a tool that may help curb Covid

MultiPlan and major insurers sued for alleged medical price

hotspot

hotspot

leisure time

hotspot